RSV Vaccine Cutting Baby Hospital Admissions by Over 80% in UK

UK Health Security Agency study of 300,000 babies shows near-85% protection when given at least 4 weeks before birth

rsv vaccine pregnancy baby health

En resumen

A UK study has found that the RSV vaccine given to pregnant women is reducing baby hospital admissions by more than 80%.
The vaccine, introduced in 2024, provides nearly 85% protection when administered at least four weeks before birth.
The study followed nearly 300,000 babies born between September 2024 and March 2025, with over 4,500 hospitalised - the vast majority whose mothers had not been vaccinated.

Resumen generado por IA

Tamaño de fuente

A UK study has found that the RSV vaccine given to pregnant women is reducing baby hospital admissions by more than 80%. The vaccine, introduced in 2024, provides nearly 85% protection when administered at least four weeks before birth. The study followed nearly 300,000 babies born between September 2024 and March 2025, with over 4,500 hospitalised - the vast majority whose mothers had not been vaccinated.

Read the full article on BBC UK News

Temas relacionados

rsv vaccine

Temaspregnancy baby health uk health security agency hospital admissions respiratory infection newborn protection

This article was originally published by BBC UK News.

Noticias relacionadas

Más sobre este temarsv vaccine

En desarrollo·hace 1 hora

Children in Poorest English Areas 40% More Likely Hospitalized for Respiratory Infections

NHS England data shows children in England's most deprived areas are 40% more likely to be hospitalized for respiratory infections. Experts from Impact on Urban Health and UCL link this to air pollution, poor housing, and systemic inequalities, urging government action on the Clean Air Act.

Guardian UK

3 min de lectura

En desarrollo·hace 5 horas

First drug to help MS patients walk now available on NHS in England

Fampridine, the first drug designed to help people with multiple sclerosis walk, is now available on the NHS in England. This 'signal booster' drug, previously rejected for cost, could benefit up to 5,000 patients annually by improving mobility and independence, a decision welcomed by patients and the MS Society.

BBC UK News

2 min de lectura

En desarrollo·hace 8 horas

First MS Walking Drug Now Available on NHS England

Fampridine, the first drug to aid walking for people with multiple sclerosis, is now available on the NHS in England. Up to 5,000 patients annually could benefit from the "signal booster" medication, which was previously rejected but is already available in other UK nations.

BBC UK News

2 min de lectura

Urgente·hace 20 horas

Parents frustrated over lack of hospital beds for baby needing heart device

Parents Dylan and Catrin Green are frustrated as their three-month-old son, Macs, diagnosed with dilated cardiomyopathy, urgently needs a Berlin heart but cannot access treatment due to a lack of specialist hospital beds in the UK.

BBC UK News

1 min de lectura

En desarrollo·ayer

Millions in England and Wales at Risk Due to Lack of 24/7 Defibrillator Access

Exclusive research reveals over 16 million people in England and Wales live more than a 1km round trip from a 24/7 defibrillator, significantly increasing cardiac arrest mortality risk. The British Heart Foundation launches a campaign to address these 'defibrillator deserts'.

Guardian UK

3 min de lectura

En desarrollo·ayer

Humanitarian Worker Monitored in London After Potential Ebola Exposure

A UK humanitarian worker, potentially exposed to Ebola while treating patients in the Democratic Republic of the Congo, is being monitored in isolation at a London hospital. The individual shows no symptoms, and the UK Health Security Agency states the risk to the general public remains low.

Guardian UK

2 min de lectura

Más sobre este temarsv vaccine